Effect of Combining Phosphodiesterase III Inhibitors With St Thomas Hospital’s Solution Used as Transplantation Preservative Solution in Isolated Rat Hearts

Improved preservation of the harvested heart with attenuation of the reperfusion injury is important for successful outcomes of cardiac transplantations. The most commonly used cardioplegic solution, to prevent ischemic changes has been St Thomas’ Hospital cardioplegic solution (STHCS). However, it...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Transplantation proceedings 2006-06, Vol.38 (5), p.1253-1258
Hauptverfasser: Besirli, K., Burhani, S.M., Arslan, C., Suzer, O., Sayin, A.G.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1258
container_issue 5
container_start_page 1253
container_title Transplantation proceedings
container_volume 38
creator Besirli, K.
Burhani, S.M.
Arslan, C.
Suzer, O.
Sayin, A.G.
description Improved preservation of the harvested heart with attenuation of the reperfusion injury is important for successful outcomes of cardiac transplantations. The most commonly used cardioplegic solution, to prevent ischemic changes has been St Thomas’ Hospital cardioplegic solution (STHCS). However, it is neither ideal nor sufficient to prevent myocardial ischemia and reperfusion injury. Phosphodiesterase inhibitors can attenuate the damage due to the injuries of ischemia and reperfusion. In this study we sought to enrich STHCS with a phosphodiesterase inhibitor to improve preservation of cardiac functions. The harvested hearts of 24 rats were divided into four groups. All hearts were mounted on a Langendorff perfusion system. After a stabilization period, cardiac arrest was maintained by STHCS. The hearts were stored in STHCS alone or with milrinone, amrinone, or enoximone for 6 hours. The reperfusion was maintained using a modified Tyrode’s solution. All hearts were compared for their preischemic and postischemic left ventricular developed pressure, +dp/dt max, −dp/dt max, duration of systole, ejection time, and time to reach peak systolic pressure. Coronary effluent was collected for lactate dehydrogenase (LDH) measurements. The initial values for all metrics were comparable between the groups. During the postreperfusion period, all hearts showed lower peak systolic pressures than the initial values. Although the amrinone group seemed to have higher values, the 25-minute result was at the border of significance and the 30-minute value, significantly higher. All hearts showed far lower results of maximum changes in contractility during the time period (+dp/dt max) versus the initial values; comparisons between groups were not significant. For the parameter of maximum changes in relaxation during the time period (−dp/dt max), while other hearts showed lower results, the amrinone group displayed values comparable to the initial ones after 20 minutes. Comparisons between groups were insignificant. While other hearts had comparable values for time of systole, the hearts applied with milrinone reached these values after 15 minutes. Group comparison for time of ejection revealed that the results at 5-minute postreperfusion were higher in the enoximone and the amrinone groups than the milrinone group. Postreperfusion 5-minute results were higher in the enoximone and the amrinone groups than the milrinone group for time to reach peak systolic pressure. LDH levels we
doi_str_mv 10.1016/j.transproceed.2006.02.062
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68575788</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0041134506001527</els_id><sourcerecordid>68575788</sourcerecordid><originalsourceid>FETCH-LOGICAL-c407t-d88c98e288785e90327885aff2c007dac6b27c27c58611d28c9ef420e899b1a33</originalsourceid><addsrcrecordid>eNqNkctu1DAUhi0EokPhFZDFgl2C7VzssEPTlolUiYpOxdJynBPGoyQefDwjseM1uuHheBLczghYIlmyjs_3n4t_Qt5wlnPG63fbPAYz4y54C9DngrE6ZyJntXhCFlzJIhO1KJ6SBWMlz3hRVmfkBeKWpViUxXNyxmvZSCGrBfl5OQxgI_UDXfqpc7Obv9KbjcfdxvcOMEIwCLRtW9rOG9e56APSLy5u6G2k642fDNJVwl00468f90hv_biPzs_0DqGnKbt-HHY0czSP7zcBEMIhBQf4S7uZtuhHE5Pos4l0BSZEfEmeDWZEeHW6z8nd1eV6ucquP31slx-uM1syGbNeKdsoEEpJVUHDCiGVqswwCMuY7I2tOyFtOpWqOe9FomEoBQPVNB03RXFO3h7rpk_9tk9r68mhhTFNDX6PulaVrFLNBL4_gjZ4xACD3gU3mfBdc6Yf3NFb_a87-sEdzYRO7iTx61OXfTel3B_pyY4EXBwBSLseHASN1sFsoXchuaR77_6nz2_8yKwH</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>68575788</pqid></control><display><type>article</type><title>Effect of Combining Phosphodiesterase III Inhibitors With St Thomas Hospital’s Solution Used as Transplantation Preservative Solution in Isolated Rat Hearts</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Besirli, K. ; Burhani, S.M. ; Arslan, C. ; Suzer, O. ; Sayin, A.G.</creator><creatorcontrib>Besirli, K. ; Burhani, S.M. ; Arslan, C. ; Suzer, O. ; Sayin, A.G.</creatorcontrib><description>Improved preservation of the harvested heart with attenuation of the reperfusion injury is important for successful outcomes of cardiac transplantations. The most commonly used cardioplegic solution, to prevent ischemic changes has been St Thomas’ Hospital cardioplegic solution (STHCS). However, it is neither ideal nor sufficient to prevent myocardial ischemia and reperfusion injury. Phosphodiesterase inhibitors can attenuate the damage due to the injuries of ischemia and reperfusion. In this study we sought to enrich STHCS with a phosphodiesterase inhibitor to improve preservation of cardiac functions. The harvested hearts of 24 rats were divided into four groups. All hearts were mounted on a Langendorff perfusion system. After a stabilization period, cardiac arrest was maintained by STHCS. The hearts were stored in STHCS alone or with milrinone, amrinone, or enoximone for 6 hours. The reperfusion was maintained using a modified Tyrode’s solution. All hearts were compared for their preischemic and postischemic left ventricular developed pressure, +dp/dt max, −dp/dt max, duration of systole, ejection time, and time to reach peak systolic pressure. Coronary effluent was collected for lactate dehydrogenase (LDH) measurements. The initial values for all metrics were comparable between the groups. During the postreperfusion period, all hearts showed lower peak systolic pressures than the initial values. Although the amrinone group seemed to have higher values, the 25-minute result was at the border of significance and the 30-minute value, significantly higher. All hearts showed far lower results of maximum changes in contractility during the time period (+dp/dt max) versus the initial values; comparisons between groups were not significant. For the parameter of maximum changes in relaxation during the time period (−dp/dt max), while other hearts showed lower results, the amrinone group displayed values comparable to the initial ones after 20 minutes. Comparisons between groups were insignificant. While other hearts had comparable values for time of systole, the hearts applied with milrinone reached these values after 15 minutes. Group comparison for time of ejection revealed that the results at 5-minute postreperfusion were higher in the enoximone and the amrinone groups than the milrinone group. Postreperfusion 5-minute results were higher in the enoximone and the amrinone groups than the milrinone group for time to reach peak systolic pressure. LDH levels were lowest in the amrinone group. In conclusion, our study revealed that adding phosphodiesterase inhibitors to STHCS improved peak systolic pressure and maximum changes in relaxation during the time period (−dp/dt max, mm Hg/s). It also decreased the LDH leakage, which corresponded to the degree of ischemic tissue damage. Amrinone seemed to result in more favorable results, which may be attributed to its additional effects on inflammation, including those on cytokines and leukocyte aggregation.</description><identifier>ISSN: 0041-1345</identifier><identifier>EISSN: 1873-2623</identifier><identifier>DOI: 10.1016/j.transproceed.2006.02.062</identifier><identifier>PMID: 16797275</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>3',5'-Cyclic-AMP Phosphodiesterases ; Animals ; Bicarbonates - pharmacology ; Calcium Chloride - pharmacology ; Cardioplegic Solutions ; Cyclic Nucleotide Phosphodiesterases, Type 3 ; Diastole ; Heart ; Heart Function Tests ; In Vitro Techniques ; Kinetics ; L-Lactate Dehydrogenase - analysis ; Magnesium - pharmacology ; Phosphodiesterase Inhibitors - pharmacology ; Potassium Chloride - pharmacology ; Rats ; Rats, Wistar ; Reperfusion ; Sodium Chloride - pharmacology ; Systole ; Tissue and Organ Harvesting - methods</subject><ispartof>Transplantation proceedings, 2006-06, Vol.38 (5), p.1253-1258</ispartof><rights>2006 Elsevier Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c407t-d88c98e288785e90327885aff2c007dac6b27c27c58611d28c9ef420e899b1a33</citedby><cites>FETCH-LOGICAL-c407t-d88c98e288785e90327885aff2c007dac6b27c27c58611d28c9ef420e899b1a33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0041134506001527$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16797275$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Besirli, K.</creatorcontrib><creatorcontrib>Burhani, S.M.</creatorcontrib><creatorcontrib>Arslan, C.</creatorcontrib><creatorcontrib>Suzer, O.</creatorcontrib><creatorcontrib>Sayin, A.G.</creatorcontrib><title>Effect of Combining Phosphodiesterase III Inhibitors With St Thomas Hospital’s Solution Used as Transplantation Preservative Solution in Isolated Rat Hearts</title><title>Transplantation proceedings</title><addtitle>Transplant Proc</addtitle><description>Improved preservation of the harvested heart with attenuation of the reperfusion injury is important for successful outcomes of cardiac transplantations. The most commonly used cardioplegic solution, to prevent ischemic changes has been St Thomas’ Hospital cardioplegic solution (STHCS). However, it is neither ideal nor sufficient to prevent myocardial ischemia and reperfusion injury. Phosphodiesterase inhibitors can attenuate the damage due to the injuries of ischemia and reperfusion. In this study we sought to enrich STHCS with a phosphodiesterase inhibitor to improve preservation of cardiac functions. The harvested hearts of 24 rats were divided into four groups. All hearts were mounted on a Langendorff perfusion system. After a stabilization period, cardiac arrest was maintained by STHCS. The hearts were stored in STHCS alone or with milrinone, amrinone, or enoximone for 6 hours. The reperfusion was maintained using a modified Tyrode’s solution. All hearts were compared for their preischemic and postischemic left ventricular developed pressure, +dp/dt max, −dp/dt max, duration of systole, ejection time, and time to reach peak systolic pressure. Coronary effluent was collected for lactate dehydrogenase (LDH) measurements. The initial values for all metrics were comparable between the groups. During the postreperfusion period, all hearts showed lower peak systolic pressures than the initial values. Although the amrinone group seemed to have higher values, the 25-minute result was at the border of significance and the 30-minute value, significantly higher. All hearts showed far lower results of maximum changes in contractility during the time period (+dp/dt max) versus the initial values; comparisons between groups were not significant. For the parameter of maximum changes in relaxation during the time period (−dp/dt max), while other hearts showed lower results, the amrinone group displayed values comparable to the initial ones after 20 minutes. Comparisons between groups were insignificant. While other hearts had comparable values for time of systole, the hearts applied with milrinone reached these values after 15 minutes. Group comparison for time of ejection revealed that the results at 5-minute postreperfusion were higher in the enoximone and the amrinone groups than the milrinone group. Postreperfusion 5-minute results were higher in the enoximone and the amrinone groups than the milrinone group for time to reach peak systolic pressure. LDH levels were lowest in the amrinone group. In conclusion, our study revealed that adding phosphodiesterase inhibitors to STHCS improved peak systolic pressure and maximum changes in relaxation during the time period (−dp/dt max, mm Hg/s). It also decreased the LDH leakage, which corresponded to the degree of ischemic tissue damage. Amrinone seemed to result in more favorable results, which may be attributed to its additional effects on inflammation, including those on cytokines and leukocyte aggregation.</description><subject>3',5'-Cyclic-AMP Phosphodiesterases</subject><subject>Animals</subject><subject>Bicarbonates - pharmacology</subject><subject>Calcium Chloride - pharmacology</subject><subject>Cardioplegic Solutions</subject><subject>Cyclic Nucleotide Phosphodiesterases, Type 3</subject><subject>Diastole</subject><subject>Heart</subject><subject>Heart Function Tests</subject><subject>In Vitro Techniques</subject><subject>Kinetics</subject><subject>L-Lactate Dehydrogenase - analysis</subject><subject>Magnesium - pharmacology</subject><subject>Phosphodiesterase Inhibitors - pharmacology</subject><subject>Potassium Chloride - pharmacology</subject><subject>Rats</subject><subject>Rats, Wistar</subject><subject>Reperfusion</subject><subject>Sodium Chloride - pharmacology</subject><subject>Systole</subject><subject>Tissue and Organ Harvesting - methods</subject><issn>0041-1345</issn><issn>1873-2623</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkctu1DAUhi0EokPhFZDFgl2C7VzssEPTlolUiYpOxdJynBPGoyQefDwjseM1uuHheBLczghYIlmyjs_3n4t_Qt5wlnPG63fbPAYz4y54C9DngrE6ZyJntXhCFlzJIhO1KJ6SBWMlz3hRVmfkBeKWpViUxXNyxmvZSCGrBfl5OQxgI_UDXfqpc7Obv9KbjcfdxvcOMEIwCLRtW9rOG9e56APSLy5u6G2k642fDNJVwl00468f90hv_biPzs_0DqGnKbt-HHY0czSP7zcBEMIhBQf4S7uZtuhHE5Pos4l0BSZEfEmeDWZEeHW6z8nd1eV6ucquP31slx-uM1syGbNeKdsoEEpJVUHDCiGVqswwCMuY7I2tOyFtOpWqOe9FomEoBQPVNB03RXFO3h7rpk_9tk9r68mhhTFNDX6PulaVrFLNBL4_gjZ4xACD3gU3mfBdc6Yf3NFb_a87-sEdzYRO7iTx61OXfTel3B_pyY4EXBwBSLseHASN1sFsoXchuaR77_6nz2_8yKwH</recordid><startdate>20060601</startdate><enddate>20060601</enddate><creator>Besirli, K.</creator><creator>Burhani, S.M.</creator><creator>Arslan, C.</creator><creator>Suzer, O.</creator><creator>Sayin, A.G.</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20060601</creationdate><title>Effect of Combining Phosphodiesterase III Inhibitors With St Thomas Hospital’s Solution Used as Transplantation Preservative Solution in Isolated Rat Hearts</title><author>Besirli, K. ; Burhani, S.M. ; Arslan, C. ; Suzer, O. ; Sayin, A.G.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c407t-d88c98e288785e90327885aff2c007dac6b27c27c58611d28c9ef420e899b1a33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>3',5'-Cyclic-AMP Phosphodiesterases</topic><topic>Animals</topic><topic>Bicarbonates - pharmacology</topic><topic>Calcium Chloride - pharmacology</topic><topic>Cardioplegic Solutions</topic><topic>Cyclic Nucleotide Phosphodiesterases, Type 3</topic><topic>Diastole</topic><topic>Heart</topic><topic>Heart Function Tests</topic><topic>In Vitro Techniques</topic><topic>Kinetics</topic><topic>L-Lactate Dehydrogenase - analysis</topic><topic>Magnesium - pharmacology</topic><topic>Phosphodiesterase Inhibitors - pharmacology</topic><topic>Potassium Chloride - pharmacology</topic><topic>Rats</topic><topic>Rats, Wistar</topic><topic>Reperfusion</topic><topic>Sodium Chloride - pharmacology</topic><topic>Systole</topic><topic>Tissue and Organ Harvesting - methods</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Besirli, K.</creatorcontrib><creatorcontrib>Burhani, S.M.</creatorcontrib><creatorcontrib>Arslan, C.</creatorcontrib><creatorcontrib>Suzer, O.</creatorcontrib><creatorcontrib>Sayin, A.G.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Transplantation proceedings</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Besirli, K.</au><au>Burhani, S.M.</au><au>Arslan, C.</au><au>Suzer, O.</au><au>Sayin, A.G.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effect of Combining Phosphodiesterase III Inhibitors With St Thomas Hospital’s Solution Used as Transplantation Preservative Solution in Isolated Rat Hearts</atitle><jtitle>Transplantation proceedings</jtitle><addtitle>Transplant Proc</addtitle><date>2006-06-01</date><risdate>2006</risdate><volume>38</volume><issue>5</issue><spage>1253</spage><epage>1258</epage><pages>1253-1258</pages><issn>0041-1345</issn><eissn>1873-2623</eissn><abstract>Improved preservation of the harvested heart with attenuation of the reperfusion injury is important for successful outcomes of cardiac transplantations. The most commonly used cardioplegic solution, to prevent ischemic changes has been St Thomas’ Hospital cardioplegic solution (STHCS). However, it is neither ideal nor sufficient to prevent myocardial ischemia and reperfusion injury. Phosphodiesterase inhibitors can attenuate the damage due to the injuries of ischemia and reperfusion. In this study we sought to enrich STHCS with a phosphodiesterase inhibitor to improve preservation of cardiac functions. The harvested hearts of 24 rats were divided into four groups. All hearts were mounted on a Langendorff perfusion system. After a stabilization period, cardiac arrest was maintained by STHCS. The hearts were stored in STHCS alone or with milrinone, amrinone, or enoximone for 6 hours. The reperfusion was maintained using a modified Tyrode’s solution. All hearts were compared for their preischemic and postischemic left ventricular developed pressure, +dp/dt max, −dp/dt max, duration of systole, ejection time, and time to reach peak systolic pressure. Coronary effluent was collected for lactate dehydrogenase (LDH) measurements. The initial values for all metrics were comparable between the groups. During the postreperfusion period, all hearts showed lower peak systolic pressures than the initial values. Although the amrinone group seemed to have higher values, the 25-minute result was at the border of significance and the 30-minute value, significantly higher. All hearts showed far lower results of maximum changes in contractility during the time period (+dp/dt max) versus the initial values; comparisons between groups were not significant. For the parameter of maximum changes in relaxation during the time period (−dp/dt max), while other hearts showed lower results, the amrinone group displayed values comparable to the initial ones after 20 minutes. Comparisons between groups were insignificant. While other hearts had comparable values for time of systole, the hearts applied with milrinone reached these values after 15 minutes. Group comparison for time of ejection revealed that the results at 5-minute postreperfusion were higher in the enoximone and the amrinone groups than the milrinone group. Postreperfusion 5-minute results were higher in the enoximone and the amrinone groups than the milrinone group for time to reach peak systolic pressure. LDH levels were lowest in the amrinone group. In conclusion, our study revealed that adding phosphodiesterase inhibitors to STHCS improved peak systolic pressure and maximum changes in relaxation during the time period (−dp/dt max, mm Hg/s). It also decreased the LDH leakage, which corresponded to the degree of ischemic tissue damage. Amrinone seemed to result in more favorable results, which may be attributed to its additional effects on inflammation, including those on cytokines and leukocyte aggregation.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>16797275</pmid><doi>10.1016/j.transproceed.2006.02.062</doi><tpages>6</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0041-1345
ispartof Transplantation proceedings, 2006-06, Vol.38 (5), p.1253-1258
issn 0041-1345
1873-2623
language eng
recordid cdi_proquest_miscellaneous_68575788
source MEDLINE; Elsevier ScienceDirect Journals
subjects 3',5'-Cyclic-AMP Phosphodiesterases
Animals
Bicarbonates - pharmacology
Calcium Chloride - pharmacology
Cardioplegic Solutions
Cyclic Nucleotide Phosphodiesterases, Type 3
Diastole
Heart
Heart Function Tests
In Vitro Techniques
Kinetics
L-Lactate Dehydrogenase - analysis
Magnesium - pharmacology
Phosphodiesterase Inhibitors - pharmacology
Potassium Chloride - pharmacology
Rats
Rats, Wistar
Reperfusion
Sodium Chloride - pharmacology
Systole
Tissue and Organ Harvesting - methods
title Effect of Combining Phosphodiesterase III Inhibitors With St Thomas Hospital’s Solution Used as Transplantation Preservative Solution in Isolated Rat Hearts
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T00%3A28%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effect%20of%20Combining%20Phosphodiesterase%20III%20Inhibitors%20With%20St%20Thomas%20Hospital%E2%80%99s%20Solution%20Used%20as%20Transplantation%20Preservative%20Solution%20in%20Isolated%20Rat%20Hearts&rft.jtitle=Transplantation%20proceedings&rft.au=Besirli,%20K.&rft.date=2006-06-01&rft.volume=38&rft.issue=5&rft.spage=1253&rft.epage=1258&rft.pages=1253-1258&rft.issn=0041-1345&rft.eissn=1873-2623&rft_id=info:doi/10.1016/j.transproceed.2006.02.062&rft_dat=%3Cproquest_cross%3E68575788%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=68575788&rft_id=info:pmid/16797275&rft_els_id=S0041134506001527&rfr_iscdi=true